CureVac (CVAC)
(Delayed Data from NSDQ)
$3.37 USD
+0.06 (1.81%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $3.24 -0.13 (-3.86%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CVAC 3.37 +0.06(1.81%)
Will CVAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CVAC
CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
Ontrak, Inc. (OTRK) Reports Q2 Loss, Lags Revenue Estimates
CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?
Other News for CVAC
Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
CVAC Stock Earnings: CureVac Misses EPS, Beats Revenue for Q2 2024
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
CureVac price target lowered by $2 at JMP Securities, here's why
CureVac: A Promising Buy Amidst Financial Stability and Innovative Vaccine Pipeline